With increasing age, people experience a loss of fat in the upper cheeks contributing to the sag and descent in the cheek and mid-face. This results in hollowness below the eyes, giving a tired and aged appearance with tear trough hollowing and descended flattened cheeks with an orbito-malar groove and trans-cheek depression called the zygomatic hollow.
The temples become hollow and depressed and the face takes on a more squared look, losing its youthful triangular appearance between the two eyes and mouth.
Nasolabial folds – the lines between the nose and the corner of the mouth – become deeper and more apparent with age. Cheek volume loss accentuates nasolabial folds, descent and loss of the malar fat mound.
Vertical depressions – known as marionette lines – appear below the corners of the mouth. Sculptra® can help re-volumise these hollows and depressions.
In patients over 45 years, Sculptra® can treat depressions in the periorbital area upper cheek, nasolabial folds, marionette lines, temple area and in front of the ears. The treatment can give a very natural and healthy look without obvious cheek “apples”. Healthcare providers who have expertise in the correction of volume defects, having undergone training and becoming fully familiarised with the product and its uses are qualified to use Sculptra®.
Sculptra® is an injectable product that contains micro particles of poly-L-lactic acid (PLLA) a synthetic polymer from the Alpha Hydroxy Acid family. This product has existed for over 30 years as dissolvable sutures and for tissue regeneration. It is typically non-toxic even in large quantities within the body, hence its suitability as a facial volumiser.
Sculptra® is biocompatible and biodegradable. It is reconstituted several days before use using sterile water and is therefore a liquid rather than a gel. The active particles are suspended in the liquid. Lignocaine is then added to the suspension to provide a more dilute suspension and local anaesthesia.
Sculptra® – used for age related facial volume loss – is injected with its local anaesthetic into the areas of depression such as the peri-orbicular area, the temples, over the malar cheek area, zygomatic hollow and towards the tear troughs. It is used very lightly in the tear troughs as a very dilute suspension in that area. Injection is typically by a cannula which reduces the number of entry points and is less traumatic to the tissue than multiple injections.